Pay in 4 interest-free payments of $5.74 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
The patient is either receiving guideline-directed medical therapy (GDMT) for cardiovascular disease or has a documented clinical reason for not receiving it (such as a contraindication to lipid-lowering agents, antiplatelets, beta-blockers, or renin-angiotensin inhibitors) ( Documentation is required for approval) Continuation of therapy: The request is for continued treatment, and
Abstract Purpose Current management of type 2 diabetes mellitus and obesity increasingly includes treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs)
Brand-name glucagon-like peptide 1 (GLP-1) medications like Wegovy* (Semaglutide) and Zepbound*(Tirzepatide) come with high out-of-pocket price tags
Lai Q, Xiang W, Li Q, Zhang H, Li Y, Zhu G, et al
Example 3 Data from studies conducted with normal human volunteers, but otherwise identical to the protocols for Example 2, was compared to the results obtained in Example 2
US$ 21.34
US$ 25.17
US$ 24.88
